Neurocrine Biosciences (NBIX) Change in Acquisitions & Divestments: 2010-2021
Historic Change in Acquisitions & Divestments for Neurocrine Biosciences (NBIX) over the last 11 years, with Dec 2021 value amounting to $174.0 million.
- Neurocrine Biosciences' Change in Acquisitions & Divestments fell 9.89% to $174.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $697.9 million, marking a year-over-year decrease of 7.01%. This contributed to the annual value of $967.5 million for FY2024, which is 0.50% down from last year.
- According to the latest figures from Q4 2021, Neurocrine Biosciences' Change in Acquisitions & Divestments is $174.0 million, which was up 8.95% from $159.7 million recorded in Q3 2021.
- In the past 5 years, Neurocrine Biosciences' Change in Acquisitions & Divestments ranged from a high of $215.9 million in Q1 2019 and a low of $46.9 million during Q3 2017.
- Its 3-year average for Change in Acquisitions & Divestments is $176.5 million, with a median of $177.4 million in 2019.
- As far as peak fluctuations go, Neurocrine Biosciences' Change in Acquisitions & Divestments plummeted by 48.80% in 2017, and later surged by 156.76% in 2019.
- Quarterly analysis of 5 years shows Neurocrine Biosciences' Change in Acquisitions & Divestments stood at $81.9 million in 2017, then soared by 42.20% to $116.4 million in 2018, then skyrocketed by 55.42% to $180.9 million in 2019, then grew by 6.74% to $193.1 million in 2020, then dropped by 9.89% to $174.0 million in 2021.
- Its last three reported values are $174.0 million in Q4 2021, $159.7 million for Q3 2021, and $202.9 million during Q2 2021.